BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 27
• 28
• 29
• 30

• Pharm Country

  Axim Biotech Receives Medical Ethical Committee Approval To Begin IBS Trial For Canchew Plus Cbdgum

  December 6, 2016

   · 

  3 min read
• Drug Development

  AbbVie Release: New Phase 2 Data Show Nearly Half Of Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond To Treatment With Ibrutinib (IMBRUVICA)

  December 6, 2016

   · 

  11 min read
• Drug Development

  Eisai Inc. Announces Final Results From Phase 3 Open-Label Study Of Rufinamide At American Epilepsy Society Annual Meeting

  December 6, 2016

   · 

  5 min read
• Business

  Breckenridge Pharmaceutical, Inc. Signs Marketing Agreement With Gland Pharma For Seven Injectable Products

  December 6, 2016

   · 

  1 min read
• Drug Development

  Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208)

  December 6, 2016

   · 

  3 min read
• Business

  SoCal’s Inogen Taps a New CEO

  December 6, 2016

   · 

  12 min read
• Drug Development

  Janssen R&D Release: Daratumumab (DARZALEX) Combination Therapy Showed Consistent Clinical Benefit For Previously-Treated Patients With Multiple Myeloma

  December 6, 2016

   · 

  19 min read
• Drug Development

  Cornerstone Pharmaceuticals, Inc. Presents Phase I Data On CPI-613 In Acute Myeloid Leukemia (AML) And T-Cell Non-Hodgkin’s Lymphoma (T-Cell NHL) At American Society of Hematology 2016

  December 6, 2016

   · 

  7 min read
• Drug Development

  Janssen R&D Release: New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise In Relapsed/Refractory Marginal Zone Lymphoma (MZL), A Rare, Incurable Type Of Non-Hodgkin’s Lymphoma

  December 6, 2016

   · 

  11 min read
• Drug Development

  Theravance Biopharma Receives FDA Fast Track Designation For Velusetrag (TD-5108) For Idiopathic And Diabetic Gastroparesis

  December 6, 2016

   · 

  10 min read